In the first half of 2024, it seemed Eli Lilly (NYSE: LLY) could do no wrong. Is Eli Lilly a good stock to buy on the dip? On Jan. 14, CEO David Ricks told investors that 2024 sales would come in at ...

Last July, Lilly's Alzheimer's disease candidate Kisunla earned approval from the FDA to treat Alzheimer's disease. Intended for early-stage patients with mild cognitive impairment, annual sales ...

In the first half of 2024, it seemed Eli Lilly (NYSE ... presentation at the annual JPMorgan Healthcare conference. On Jan. 14, CEO David Ricks told investors that 2024 sales would come in ...

Eli Lilly has revised its revenue forecast for 2024 after seeing weaker-than-expected growth for its diabetes and obesity therapies – but still said sales rose around a third over the prior year.

GLP-1 drugs have become all the rage for weight loss, with sales for drugs like Novo Nordisk's Ozempic and Eli Lilly's (NYSE: LLY) Mounjaro skyrocketing over the past year. However, Eli Lilly ...

Sales for the 2024 holiday shopping season turned out to be robust and better than expected, as easing inflation on ...

Eli Lilly unexpectedly lowered its full-year 2024 guidance. The miss appears to stem from a lack of the typical December scripts boost. The stock is attractively valued at current levels.

Pulitzer Prize-winning cartoonist Darrin Bell has been arrested on suspicion of possessing child sexual abuse videos, including AI-generated material. The Sacramento County Sheriff's Office said ...

Telehealth company Ro will offer single-dose vials of Eli Lilly's obesity therapy Zepbound in an expansion of the ways patients with a prescription can access the drug. The agreement means Ro has ...